This topic contains a solution. Click here to go to the answer

Author Question: The nurse explains that atropine (Atropair) increases heart rate in which manner? 1. Blocking the ... (Read 96 times)

JMatthes

  • Hero Member
  • *****
  • Posts: 578
The nurse explains that atropine (Atropair) increases heart rate in which manner?
 
  1. Blocking the beta receptors of the parasympathetic nervous system.
  2. Directly stimulating the sympathetic nervous system.
  3. Potentiating the effects of acetylcholine on nicotinic receptors.
  4. Blocking the effects of acetylcholine by occupying muscarinic receptors.

Question 2

The physician orders potassium chloride (KCl) intravenous (IV) for the patient. The nurse administers this drug intravenous (IV) push. What will be the most likely outcome for this patient?
 
  1. The patient will most likely experience cardiac arrest.
  2. The patient will not experience adverse effects if the push was given slowly.
  3. The patient will most likely experience tissue necrosis at the injection site.
  4. The patient will most likely experience renal failure.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

mohan

  • Sr. Member
  • ****
  • Posts: 362
Answer to Question 1

4
Rationale 1: Atropine occupies muscarinic receptors.
Rationale 2: Atropine blocks parasympathetic actions of acetylcholine.
Rationale 3: Atropine does not potentiate acetylcholine effects on nicotinic receptors.
Rationale 4: Atropine is a cholinergic-blocking agent that occupies muscarinic receptors.
Global Rationale: Atropine is a cholinergic-blocking agent that occupies muscarinic receptors. It is classified as an anticholinergic agent because it inhibits the effects of the parasympathetic nervous system, which induces the fight-or-flight responses of the sympathetic nervous system.

Answer to Question 2

1
Rationale 1: Potassium chloride (KCl) must never be administered intravenous (IV) push, as bolus injections can overload the heart and cause cardiac arrest.
Rationale 2: Potassium chloride must never be administered via intravenous (IV) push, even if slowly, as cardiac arrest may result.
Rationale 3: Although tissue necrosis may occur, this is not the primary concern.
Rationale 4: Renal failure is not the most concerning outcome of administering potassium chloride intravenous (IV) push.
Global Rationale: Potassium chloride (KCl) must never be administered intravenous (IV) push, as bolus injections can overload the heart and cause cardiac arrest. Potassium chloride must never be administered via intravenous (IV) push, even if slowly, as cardiac arrest may result. Cardiac failure, not renal failure, is the most likely outcome of administering potassium chloride intravenous (IV) push. Although tissue necrosis may occur, this is not the primary concern.





 

Did you know?

Over time, chronic hepatitis B virus and hepatitis C virus infections can progress to advanced liver disease, liver failure, and hepatocellular carcinoma. Unlike other forms, more than 80% of hepatitis C infections become chronic and lead to liver disease. When combined with hepatitis B, hepatitis C now accounts for 75% percent of all cases of liver disease around the world. Liver failure caused by hepatitis C is now leading cause of liver transplants in the United States.

Did you know?

Every 10 seconds, a person in the United States goes to the emergency room complaining of head pain. About 1.2 million visits are for acute migraine attacks.

Did you know?

Drug-induced pharmacodynamic effects manifested in older adults include drug-induced renal toxicity, which can be a major factor when these adults are experiencing other kidney problems.

Did you know?

A strange skin disease referred to as Morgellons has occurred in the southern United States and in California. Symptoms include slowly healing sores, joint pain, persistent fatigue, and a sensation of things crawling through the skin. Another symptom is strange-looking, threadlike extrusions coming out of the skin.

Did you know?

In Eastern Europe and Russia, interferon is administered intranasally in varied doses for the common cold and influenza. It is claimed that this treatment can lower the risk of infection by as much as 60–70%.

For a complete list of videos, visit our video library